BrainStorm Cell Therapeutics Partners with NEALS, the ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn’s Phase III ALS Study

BrainStorm Cell Therapeutics, Inc. announced that BCLI will donate biospecimens from NurOwn’s placebo-controlled Phase III ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community.